Vaughan M. M., Evans B. D., Baranyai J., Weitzer M. J.
Department of Medicine, The Royal Marsden Hospital, Fulham Rd, London, U.K; Oncology Unit, Auckland Hospital, Park Rd, Auckland; Department of Histopathology, Greenlane Hospital, Greenlane, Auckland, New Zealand.
Int J Gynecol Cancer. 1998 Jan;8(1):16-22. doi: 10.1046/j.1525-1438.1998.09711.x.
Vaughan MM, Evans BD, Weitzer MJ. Survival of patients with primary fallopian tube carcinoma. Int J Gynecol Cancer 1998; 8: 16-22. Thirty-seven patients with primary fallopian tube carcinoma (PFTC) presenting between 1952 and 1995 were studied. The mean age was 57 years. Seven patients had stage I disease, 20 stage II, 8 stage III, and 2 stage IV. Actuarial 5-year survivals were 73% for stage I, 33% for stage II and 0% for stage III. Stage was a significant predictor of survival at 5 years (Stage I vs. III, P = 0.0006; stage II vs. III, P = 0.0001), however, the majority of patients, even with early stage disease, died of progressive PFTC within 10 years. Grade appeared highly significant at 5 and 10 years (Grades 1 & 2 vs. 3, P = 0. 0023). Neither age nor lymphocytic infiltrate appeared definitely predictive of survival. Eleven of 22 stage II patients received adjuvant treatment. While their median and 5-year survivals were superior to those not receiving adjuvant treatment (51 vs. 30 months, 47% vs. 22%), the difference was not statistically significant. This retrospective analysis confirms the poor prognosis of patients with PFTC. The majority of patients, even with early stage tumors, eventually succumb to their disease. Larger studies may identify a group of patients potentially curable with surgery alone, and clarify the role of adjuvant therapy.
沃恩·M·M、埃文斯·B·D、韦策尔·M·J。原发性输卵管癌患者的生存率。《国际妇科癌症杂志》1998年;8:16 - 22。对1952年至1995年间出现的37例原发性输卵管癌(PFTC)患者进行了研究。平均年龄为57岁。7例为Ⅰ期疾病,20例为Ⅱ期,8例为Ⅲ期,2例为Ⅳ期。Ⅰ期的5年精算生存率为73%,Ⅱ期为33%,Ⅲ期为0%。分期是5年生存率的显著预测因素(Ⅰ期与Ⅲ期,P = 0.0006;Ⅱ期与Ⅲ期,P = 0.0001),然而,大多数患者,即使是早期疾病患者,也在10年内死于进展性PFTC。分级在5年和10年时似乎具有高度显著性(1级和2级与3级,P = 0.0023)。年龄和淋巴细胞浸润似乎都不能明确预测生存率。22例Ⅱ期患者中有11例接受了辅助治疗。虽然他们的中位生存期和5年生存率优于未接受辅助治疗的患者(51个月对30个月,47%对22%),但差异无统计学意义。这项回顾性分析证实了PFTC患者预后不良。大多数患者,即使是早期肿瘤患者,最终也会死于该病。更大规模的研究可能会确定一组仅通过手术可能治愈的患者,并阐明辅助治疗的作用。